Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Tivicay

Tivicay 10 mg film-coated tablets Tivicay 25 mg film-coated tablets Tivicay 50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-129160 · Präparat HOS-096689

Table 3: Drug Interactions Medicinal products Interaction Recommendations concerning by therapeutic areas Geometric mean change co-administration (%) HIV-1 Antiviral Agents Non-nucleoside Reverse Transcriptase Inhibitors Etravirine without Dolutegravir  Etravirine without boosted protease inhibitors boosted protease AUC  71% decreased plasma dolutegravir concentration. The inhibitors Cmax  52% recommended adult dose of dolutegravir is 50 mg Cτ  88% twice daily when co-administered with etravirine without boosted protease inhibitors. In paediatric Etravirine  patients the weight-based once daily dose should (induction of UGT1A1 and be administered twice daily. Dolutegravir should CYP3A enzymes) not be used with etravirine without co- administration of atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir in INI- resistant patients (see further below in table). Lopinavir/ritonavir + Dolutegravir  No dose adjustment is necessary. etravirine AUC  11% Cmax  7% Cτ  28% LPV  RTV  Darunavir/ritonavir + Dolutegravir  No dose adjustment is necessary. etravirine AUC  25% Cmax  12% Cτ  36% DRV  RTV  Efavirenz Dolutegravir  The recommended adult dose of dolutegravir is AUC  57% 50 mg twice daily when co-administered with Cmax  39% efavirenz. In paediatric patients the weight-based Cτ  75% once daily dose should be administered twice daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) atazanavir (HOS-086180) protease (HOS-085623) etravirine (HOS-088088) darunavir (HOS-086181) efavirenz (HOS-087947) ritonavir (HOS-084521)